Loading...

ARVN ARVINAS INC Company Mergers 8-K Filing

RVNS

RVN

ARVINAS INC

(ARVN)

2026 8-K

Financial Results Announced

License Agreement Signed

FDA Approval Announcement

Positive Clinical Data

Financial Results Report

Management Changes

Preclinical Data Release

Financial Update

Data Announcement

Positive Trial Results

Workforce Reduction

Financial Statements

Product Expansion

New Product Launches

Product Expansion

Management Changes

Product Expansion

Clinical Trial Results

Clinical Trial Results

Financial Results

Lease Termination

Clinical Trial Update

Lease Amendment

Lease Amendments

Clinical Trial Update

Clinical Trial Update

Financial Results

Lease Termination

Financial Results Announcement

Appointment of CFO

Agreement with Yale University

Appointment of Officers

Annual Meeting of Stockholders

Transaction with Novartis

Clinical Trial Update

Earnings Reports

Entry into Material Definit...

Appointment of Chief Medica...

Financial Results Announcement

Departure of CFO and Appoin...

Interim Data Announcement

Private Placement

Financial Results Announcement

Clinical Trial Data Announc...

Financial Results Announcement

Amendment of Bylaws

Interim Data Announcement

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Guidance Update

External Links:

On May 11, 2026, Arvinas, Inc. entered a License Agreement with Rigel Pharmaceuticals for exclusive rights to developing and commercializing VEPPANU™, receiving a $70 million upfront payment and potential additional payments of up to $320 million. This agreement is significant as it opens new revenue sources and facilitates broader commercialization of their product in partnership with Rigel.

AI Assistant

ARVINAS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.